Mer­ck goes in deep­er with Keytru­da/Lyn­parza com­bo; PureTech un­veils stem cell ther­a­py start­up

→ Mer­ck is open­ing up a new wing of its Keytru­da pipeline, de­vot­ing it to a slate of new Phase III com­bi­na­tion stud­ies with Lyn­parza in treat­ing prostate can­cer. Re­searchers spot­ted an­ti-tu­mor ac­tiv­i­ty in 3 co­horts, send­ing them the sig­nal they were look­ing for to pile on piv­otal stud­ies in search of a new mar­ket. “These promis­ing da­ta pre­sent­ed at AS­CO GU cou­pled with the sig­nif­i­cant un­met med­ical need in pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, pro­pelled us to ini­ti­ate three new Phase 3 tri­als to fur­ther eval­u­ate these KEYTRU­DA com­bi­na­tion reg­i­mens,” not­ed Mer­ck’s Roy Baynes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER